Applications and prospects of molecularly targeted drugs combined with CAR-T cell therapy to treat multiple myeloma

Area of Science:

• Oncology
• Immunotherapy
• Pharmacology

Background:

• Chimeric antigen receptor T (CAR-T) cell therapy is a precision immunotherapy with potential against various cancers.
• Challenges include antigen escape, tumor microenvironment (TME) suppression, and CAR-T cell depletion.
• Molecularly targeted drugs offer a strategy to enhance CAR-T efficacy.

Purpose of the Study:

• To review molecularly targeted drugs used in combination with CAR-T cell therapy for multiple myeloma (MM).
• To highlight the synergistic effects of combined therapies in overcoming CAR-T limitations.

Main Methods:

• Literature review of studies combining CAR-T cell therapy and molecularly targeted drugs for MM.
• Analysis of mechanisms by which targeted drugs enhance CAR-T activity and modulate the TME.

Main Results:

• Molecularly targeted drugs can overcome antigen escape and TME suppression.
• Combination therapy boosts anti-cancer activity and inhibits immune escape.
• This combined approach is gaining attention for personalized MM treatment.

Conclusions:

• Combining CAR-T cell therapy with molecularly targeted drugs is a promising strategy for treating multiple myeloma.
• Targeted drugs enhance CAR-T cell function and improve the tumor microenvironment.
• Further research into this combination therapy is warranted for optimizing cancer treatment.